PrecivityAD2, a blood test for Alzheimer's-related amyloid pathology, was cleared by FDA on Aug. 20, 2026 for adults age 40 and older with signs of cognitive impairment. For primary care patients, what comes next is coverage and wider rollout starting Oct.
1, 2026. According to C2N Diagnostics in the FDA clearance announcement, the clearance makes PrecivityAD2 the first FDA-cleared Alzheimer's blood test down to age 40. It does not approve screening without symptoms or a stand-alone diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does the test work?
- Why does age 40 matter?
- What will change in primary care?
- What comes next for access?
How does the test work?
PrecivityAD2 uses high-resolution mass spectrometry to measure plasma Aβ42/40 and p-tau217/np-tau217 ratios. As reported by NeurologyLive in its test description, those results are combined into an Amyloid Probability Score 2.
The score has three results: negative, positive, or intermediate "likely positive." In a 1,142-person symptomatic validation cohort versus amyloid PET or spinal fluid testing, C2N reported 97.6% positive predictive value and 93.1% negative predictive value. The result must be read with a standard clinical workup by a clinician experienced in cognitive impairment. Patient Care Online notes in its clearance summary that the test is not cleared for asymptomatic screening.
Why does age 40 matter?
Younger-onset Alzheimer's affects people under 65. Clinicians often miss it because they do not expect dementia in younger patients, according to the Alzheimer's Association. Earlier tests left much of that group outside the label.
PrecivityAD2 was the third FDA-cleared Alzheimer's amyloid blood test, after Fujirebio Lumipulse in May 2025 and Roche Elecsys pTau181 in October 2025, both limited to age 55 and older. The age-40 indication directly affects adults in their 40s, 50s, and early 60s with memory, language, planning, or work problems. For them, a blood test can shorten the path from concern to amyloid assessment.
What will change in primary care?
Many patients first report symptoms to a primary care doctor, not a specialist. A 1,310-patient study by 165 physicians found diagnostic accuracy rose from 65% to 93% after PrecivityAD2 results, matching specialists.
That supports earlier triage in the office where most evaluations start. A positive, negative, or intermediate score helps decide who needs prompt referral, who needs other causes checked, and who may qualify for trial referral. Patients can prepare for that visit:.
- list symptoms, start date, and change in work or daily tasks
- bring medications, sleep, mood, thyroid, vitamin, and head-injury history
- bring a family member who has seen the changes
- ask what workup will accompany the blood test
What comes next for access?
Coverage and rollout are the next step. C2N and Anthem described in the coverage announcement that Anthem will cover PrecivityAD2 from Oct. 1, 2026.
The FDA-cleared kit is expected later in 2026, while the CLIA lab version remains available. Congress's ASAP Act would authorize Medicare screening coverage. Ask your clinic whether it orders the CLIA version now, which insurer rules apply, and what follow-up testing your result would require.
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Changed and What Comes Next for Primary Care Patients
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: Accuracy, Limits, and Evidence Gaps for Primary Care Patients
- Strengths-Based Dementia Care in the 2026 NIA Report: What Changed and What Comes Next for Spouses and Partners
